{
    "organizations": [],
    "uuid": "46666f1c126f4ac208a6527d6f7fb2c35a2bdc2b",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-axsome-therapeutics-reports-q4-los/brief-axsome-therapeutics-reports-q4-loss-per-share-0-31-idUSASB0C95O",
    "ord_in_thread": 0,
    "title": "BRIEF-Axsome Therapeutics Reports Q4 Loss Per Share $0.31",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 7 (Reuters) - Axsome Therapeutics Inc:\n* AXSOME THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE\n* Q4 LOSS PER SHARE $0.31 * AXSOME THERAPEUTICS - BELIEVES CASH AT DEC 31, 2017 TO BE SUFFICIENT TO FUND ANTICIPATED OPERATIONS INTO Q3 2019\n* AT DECEMBER 31, 2017, AXSOME HAD $34.0 MILLION OF CASH COMPARED TO $36.6 MILLION OF CASH AT DECEMBER 31, 2016 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-07T20:15:00.000+02:00",
    "crawled": "2018-03-08T17:10:24.042+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "axsome",
        "therapeutic",
        "inc",
        "axsome",
        "therapeutic",
        "report",
        "fourth",
        "quarter",
        "full",
        "year",
        "financial",
        "result",
        "provides",
        "business",
        "update",
        "q4",
        "loss",
        "per",
        "share",
        "axsome",
        "therapeutic",
        "belief",
        "cash",
        "dec",
        "sufficient",
        "fund",
        "anticipated",
        "operation",
        "q3",
        "december",
        "axsome",
        "million",
        "cash",
        "compared",
        "million",
        "cash",
        "december",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}